Young TK, Li JW, Kang A, Heerspink HJL, et al. Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program. Diabetologia 2021;64:2402-2414.
PMID: 34448033